Akari Therap(AKTX.US)

Last Updated 19:00:00 ET
longbridge loading

Akari Therapeutics Delays Quarterly SEC Filing

Tip Ranks·
US
AKTX
+5.71%
Tip Ranks·
US
AKTX
+5.71%

Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase | AKTX Stock News

StockTitan·
US
AKTX
+5.71%
StockTitan·
US
AKTX
+5.71%

Why Akari Therapeutics Stock Is Surging On Thursday?

benzinga_article·
US
AKTX
+5.71%
benzinga_article·
US
AKTX
+5.71%

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading

Fidelity·
US
AKTX
+5.71%
US
NOK
-1.78%
US
EDAP
+1.13%
Fidelity·
US
AKTX
+5.71%
US
NOK
-1.78%
US
EDAP
+1.13%

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga_article·
US
MGNX
+4.25%
US
WOK
-38.39%
US
USBC
-5.56%
benzinga_article·
US
MGNX
+4.25%
US
WOK
-38.39%
US
USBC
-5.56%

Pre-market hot trades in US stocks: Akari Therap pre-market down 9.25%; SKK pre-market up 7.91%

Price Alert·
US
AKTX
+5.71%
US
SKK
-4.39%
Price Alert·
US
AKTX
+5.71%
US
SKK
-4.39%

European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading

Fidelity·
US
BNTX
-0.38%
US
NOK
-1.78%
US
SQNS
-3.80%
Fidelity·
US
BNTX
-0.38%
US
NOK
-1.78%
US
SQNS
-3.80%

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload | AKTX Stock News

StockTitan·
US
AKTX
+5.71%
StockTitan·
US
AKTX
+5.71%
© 2026 Longbridge｜Disclaimer